These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30476551)

  • 1. Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.
    Huang YT; Su Y; Kim SJ; Nichols P; Burack D; Maloy M; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):791-799. PubMed ID: 30476551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34
    Huang YT; Kim SJ; Lee YJ; Burack D; Nichols P; Maloy M; Perales MA; Giralt SA; Jakubowski AA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1759-1766. PubMed ID: 28668490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation.
    Fang J; Su Y; Zavras PD; Raval AD; Tang Y; Perales MA; Giralt S; Stern A; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1937-1947. PubMed ID: 32640313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.
    Huang YT; Neofytos D; Foldi J; Kim SJ; Maloy M; Chung D; Castro-Malaspina H; Giralt SA; Papadopoulos E; Perales MA; Jakubowski AA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1480-1486. PubMed ID: 27178374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus resistance in CD34
    Kim SJ; Huang YT; Foldi J; Lee YJ; Maloy M; Giralt SA; Jakubowski AA; Papanicolaou GA
    Transpl Infect Dis; 2018 Jun; 20(3):e12881. PubMed ID: 29570237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation.
    Karantoni E; Zavras PD; Su Y; Fang J; Tamari R; Cho C; Perales MA; Stern A; Papanicolaou GA
    Transplant Cell Ther; 2022 Jul; 28(7):403.e1-403.e7. PubMed ID: 35476955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study.
    Zavras P; Su Y; Fang J; Stern A; Gupta N; Tang Y; Raval A; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1482-1491. PubMed ID: 32315708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
    Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
    Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
    Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
    Transplant Cell Ther; 2024 Aug; 30(8):792.e1-792.e12. PubMed ID: 38838781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
    Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
    Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK; Silveira FP; Benedict K; Cleveland AA; Kauffman CA; Schuster MG; Dubberke ER; Husain S; Paterson DL; Chiller T; Pappas P
    Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact.
    Lee YJ; Huang YT; Kim SJ; Maloy M; Tamari R; Giralt SA; Papadopoulos EB; Jakubowski AA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):174-8. PubMed ID: 26318614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
    Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
    Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
    Marty FM; Winston DJ; Chemaly RF; Mullane KM; Shore TB; Papanicolaou GA; Chittick G; Brundage TM; Wilson C; Morrison ME; Foster SA; Nichols WG; Boeckh MJ;
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):369-381. PubMed ID: 30292744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
    Kim T; Lee YM; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Jung JH; Shin S; Kim YH; Kang YA; Lee YS; Lee JH; Lee JH; Lee KH; Park SK; Han DJ; Kim SH
    Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
    Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
    J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
    Junghanss C; Storb R; Maris MB; Carter RA; Sandmaier BM; Maloney DG; McSweeney PA; Corey L; Boeckh M
    Br J Haematol; 2003 Nov; 123(4):662-70. PubMed ID: 14616970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.